Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020437 (
hypercalcemia
)
10,293
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Six patients with progressive chronic renal failure not yet requiring dialysis and not consuming supplemental calcium or vitamin D developed
hypercalcemia
. Three had proven and 1 suspected tertiary hyperparathyroidism, 1 parathyroid carcinoma and 1 aplastic bone. None of the 3 patients who underwent bone biopsy had heavy bone aluminum staining. The patients with proven parathyroid-mediated
hypercalcemia
had marked elevation of C-terminal parathyroid hormone and
alkaline phosphatase
values and, when performed, radiographs consistent with osteitis fibrosa. When these findings are absent or the diagnosis is otherwise uncertain, a bone biopsy may provide a definitive diagnosis and guide management.
...
PMID:Hypercalcemia in patients with advanced chronic renal failure not yet requiring dialysis. 275 79
Clinical investigations have shown that 1 alpha-hydroxycholecalciferol (oxydevit, alphacalcidiol) and 1 alpha, 25-dihydroxycholecalciferol (rocaltrol) are act vitamin D3 agents producing a positive clinical effect in different types of osteoporosis and osteomalacia. Clinical improvement of the patients' status (alleviation of the pain syndrome, an increase in motor activity) was noted in 1-2 mos., an x-ray picture of regeneration of the bone structure of both axial and peripheral skeleton--in 6-12 mos. after the initiation of therapy. Therapy was attended by an increase in the serum content of total and ionized calcium, the return of
alkaline phosphatase
activity to normal, and a decrease in the level of parathormone. During prolonged therapy these agents administered at daily doses of 0.25-2 micrograms caused no pathological side-effects and
hypercalcemia
. In osteoporotic conditions all these drugs were equal in their clinical effectiveness. Rocaltrol has some advantages in the presence of associated liver pathology.
...
PMID:[Comparative evaluation of the effectiveness of vitamin D3 preparations (1-alpha-hydroxy- and 1-alpha,25-dihydroxycholecalciferol in various forms of osteoporosis and osteomalacia]. 276 60
Since dialysis solutions in CAPD are now nearly aluminum free, the only source for elevated aluminum levels are aluminum-containing phosphate binders. Elimination with CAPD is insufficient to prevent aluminum accumulation. Therefore, we investigated a phosphate binder consisting of calcium alginate, a natural polyuronic acid, containing 100 mg calcium/g substance in 14 patients on CAPD over a period of one year. The patients had previously been treated with aluminum-containing phosphate binders for a period of 24.3 +/- 21.3 months. During a period of 3 weeks before changing to the new phosphate binder the mean (+/- SD) serum phosphorus concentration was 1.8 +/- 0.4 mmol/l, while at the end of one year of treatment with calcium alginate the concentration was 1.6 +/- 0.4 mmol/l. In order to lower serum phosphorus to this level, it was necessary to increase the mean (+/- SD) amount of calcium alginate from 6.9 +/- 1.3 g per day at the beginning of the study to 8.3 +/- 2.1 g per day at the end. The mean (+/- SD) serum calcium concentration did not change throughout the study period. Serum levels of
alkaline phosphatase
, 1.25 (OH)2 vitamin D3, and intact parathyroid hormone did not change as well. The mean (+/- SD) serum aluminum level declined from 36.0 +/- 20 to 14.0 +/- 11.3 micrograms/l after 6 months (p less than 0.001). In conclusion, calcium alginate is a good alternative to aluminum-containing phosphate binders and to phosphate binders on a calcium base as it does not lead to
hypercalcemia
. It prevents aluminum intoxication and has no serious side effects.
...
PMID:Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD. 276 87
We have measured classic markers of bone turnover, serum
alkaline phosphatase
(sAP), urinary hydroxyproline/creatinine ratio (uOH-Prol/creatinine) and osteocalcin (sBGP), in two bone disorders characterized by an increase in bone remodelling, namely Paget's disease of bone and primary hyperparathyroidism (PHPT) and in two other bone diseases characterized by an increase in bone resorption without the concomitant increase in bone formation,
hypercalcaemia
of malignancy (HM) and involutional osteoporosis (IO). Serum BGP was increased in patients with Paget's disease of bone (6.7 +/- 3.1; n = 25; p less than 0.01) and in PHPT patients (8.3 +/- 5.3; n = 20; p less than 0.005) with respect to control patients (4.2 +/- 1.2 ng/ml; n = 12). Two subgroups of patients with high and normal levels of sBGP were found in both pathologies. Serum BGP was decreased in HM patients (2.1 +/- 1.7; n = 9; p less than 0.01) and in IO patients (1.9 +/- 1.4; n = 31; p less than 0.001). Two subgroups of patients with normal and low sBGP values were found in these two last disorders. A positive linear correlation was found between sBGP and sAP (y = 14.6x + 73.7; r = 0.44; p less than 0.05) and between sBGP and uOH-Prol/creatinine (y = 0.008x + 0.007; r = 0.67; p less than 0.001) in Paget's disease of bone.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis. 278 49
A 14-year-old Turkish boy had severe rickets that had been clinically evident since he was 2 years of age. When he was 5 years of age, he had normal serum calcium and phosphorus levels and increased
alkaline phosphatase
activity. Treatment with modest dosages of vitamin D (5000 U/d for 3 weeks) resulted in
hypercalcemia
. At 10 years of age, high-dose vitamin D (40,000 U/d) plus phosphorus (1.1 g/d) therapy for 20 days resulted in symptomatic nephrolithiasis. When, 14 years of age, he had normocalcemia, hypophosphatemia, increased
alkaline phosphatase
activity, and normal circulating parathyroid hormone concentration. Levels of 25-hydroxyvitamin D were normal but those of 1,25-dihydroxyvitamin D were markedly increased. Rickets and osteopenia were evident on radiographs, and osteomalacia was present on trabecular bone obtained at biopsy. Balance study results showed increased intestinal absorption of calcium and phosphorus, hypercalciuria, and increased urinary phosphorus excretion. This patient manifests an unusual form of hypophosphatemic rickets in which hypercalciuria is a cardinal feature. In contrast with most varieties of hypophosphatemia, this disorder is characterized by appropriately increased production of 1,25-dihydroxyvitamin D in response to hypophosphatemia. It is recommended that urinary calcium excretion be assessed in all patients with hypophosphatemic rickets so that appropriate therapy will be instituted.
...
PMID:Hypercalciuric hypophosphatemic rickets, mineral balance, bone histomorphometry, and therapeutic implications of hypercalciuria. 278 97
Biochemical indices of bone turnover were determined in a cluster sample of 427 apparently healthy elderly subjects aged 60 years and over. Plasma calcium concentrations corrected for albumin were not significantly different between elderly men and women, but were higher compared with values in younger Chinese of the same sex. The prevalence of
hypercalcemia
(greater than 2.75 mmol/L) in the elderly (0.2%) was lower than in Caucasian populations. Plasma phosphate concentrations were higher in women, but lower than in young adults. Plasma
alkaline phosphatase
activity was higher in women compared with values for men, and higher compared with values for young adults. Plasma 25-hydroxyvitamin D was lower in elderly women than elderly men, but was similar to values in younger subjects. Urinary calcium: creatinine and hydroxyproline: creatinine ratios were higher in women. The values were comparable to those for Caucasian postmenopausal women, suggesting that Chinese elderly subjects had similar bone turnover rates.
...
PMID:Some biochemical indices of bone turnover in elderly Chinese. 280 21
A strong correlation between the biochemical manifestations of hyperparathyroidism and the volume of abnormal parathyroid tissue could be used to guide the extent of surgical exploration and parathyroid gland resection (i.e., finding a small "adenoma" in a patient with marked
hypercalcemia
would dictate further exploration). We examined this relationship in patients for whom data were collected prospectively (n = 14) and retrospectively (n = 27). We considered only patients cured after excision of a single gland and glands for which a three-dimensional description or volume of water displacement was available. To exclude artifactually elevated serum concentrations of parathyroid hormone (PTH), PTH values were used only from patients with levels of serum creatinine less than 2 mg/dl. To accommodate different assays, highest preoperative PTH, ionized calcium, and
alkaline phosphatase
(AP) values were expressed as percent above upper normal limit. There was excellent agreement (r = 0.93, p less than 0.05) between measured and calculated gland volume. In the prospective study (but not in the retrospective study) there was a significant (p less than 0.05) correlation (r = 0.61) between gland volume and highest preoperative total calcium value; however, there was considerable variation in gland size in patients with similar calcium levels. In neither study was there a significant correlation between gland volume and any of the following: calcium, ionized calcium, midregional PTH, carboxyterminal PTH, or intact PTH,
alkaline phosphatase
, and urine cyclic adenosine monophosphate (AMP). In the prospective study there was a tendency for urine cyclic AMP, ionized calcium, and AP to increase with increasing gland volume (r = 0.42, 0.45, and 0.51, respectively). Preoperative measurements of calcium, PTH, urine cyclic AMP, and AP are too inconsistent to rely on for determining the extent of parathyroid gland resection.
...
PMID:Can the volume of abnormal parathyroid tissue be predicted by preoperative biochemical measurement? 282 7
A tumor-derived factor believed to cause
hypercalcemia
by acting on the parathyroid hormone (PTH) receptor was recently purified, cloned, and found to have NH2-terminal sequence homology with PTH. The 1-34 region of this protein was synthesized, evaluated for its postreceptor effects on the ROS 17/2.8 cell line, and its properties were compared to 1-34 PTH. Both 1-34 human humoral
hypercalcemia
factor (HCF) and 1-34 PTH stimulated adenylate cyclase with an effective concentration (EC)50 of approximately 1 nM. The extent of stimulation by both peptides was equally enhanced by dexamethasone. They both had a pronounced inhibitory effect on growth in the presence of dexamethasone, with an EC50 of approximately 0.1 nM, reduced
alkaline phosphatase
(AP) activity by approximately 70% in the absence of dexamethasone and by approximately 80% in the presence of dexamethasone with an EC50 of 0.03 nM, and when present at a concentration of 10 nM, reduced AP mRNA levels (estimated by Northern analysis) by approximately 80% in the presence or absence of dexamethasone. Thus, in addition to similar dose-response curves for adenylate cyclase stimulation, both HCF and PTH produced identical postreceptor effects in ROS 17/2.8 cells. These effects of HCF are probably mediated by the interaction of the tumor-derived factor with the PTH receptor.
...
PMID:Comparison of postreceptor effects of 1-34 human hypercalcemia factor and 1-34 human parathyroid hormone in rat osteosarcoma cells. 283 Mar 17
Osteitis deformans is a focal disease of the osteoclasts characterised by increased bone resorption subsequently followed by increased bone formation leading to abnormal bone. A viral etiology seems increasingly probable, but remains unproven. 5-30% of the patients present with symptoms such as pain, deformity and fracture. Hearing loss, nerve- or root-compression, arthrosis and hyperuricaemia may complicate the disease while malignant degeneration,
hypercalcemia
and high output cardiac failure are rare. The diagnosis is based on X-ray findings but biopsy may be necessary in selected cases. The extent of the disease is revealed by bone scintigraphy and the activity of the disease reflected by urine hydroxyproline excretion and serum
alkaline phosphatase
.
...
PMID:[Paget's osteitis deformans. Epidemiology and clinical picture]. 292 39
The abnormalities of calcium-phosphorum metabolism observed in hyperthyroidism (tendency to
hypercalcaemia
with subsequent functional hypoparathyroidism, increase in serum
alkaline phosphatase
and in hydroxyprolinuria) essentially result from excessive mobilization of bone calcium and phosphates by the thyroid hormones themselves. Histomorphometric studies have shown that the skeletal repercussions of hyperthyroidism are almost constant. There is, in particular, excessive bone remodelling due to increased bone-forming and bone-resorbing cellular activities. However, since bone resorption is quantitatively more stimulated than bone formation, the physiological bone loss is accelerated and is only partly repaired by re-establishment of the normal thyroid function.
...
PMID:[Phospho-calcium and bone metabolism in hyperthyroidism in adults]. 293 96
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>